Welcome to Aimmune Therapeutics, Inc., a Nestlé Health Science Company, and Seres Therapeutics, Inc. US Medical Affairs Twitter page! Please see our community guidelines below.
Recent research highlights a concerning uptick in community-acquired #Cdiff infection, challenging the traditional association with healthcare exposure. #CDI#InfectionControl
In 1974, Tedesco et al made a significant breakthrough, revealing that 21% of patients treated with #clindamycin developed diarrhea, signaling a crucial turning point in understanding the connection between #antibiotics and #Clostridioidesdifficile infection. #Cdiff
In 1935, Hall and O'Toole made a groundbreaking discovery by isolating #Clostridioidesdifficile from the stool of a healthy newborn, marking a significant milestone in microbiology. #Cdiff#Microbiology
#DYK: Around 5% of adults and up to 70% of infants are colonized by #Clostridioidesdifficile, with higher prevalence rates observed in hospitalized patients and nursing home residents. #Cdiff
#PopQuiz: Recent travel, family history of #Cdiff infection, and vaccination status are significant patient related risk factors for #Clostridioidesdifficile infection.
#PopQuiz: Analysis of #Cdiff infection cases from the United States supports the significance of the North American pulsed field gel electrophoresis type 1 (NAP1) strain in determining patient outcomes.
Studies during the initial #COVID19 wave revealed a notable decline in the #Cdiff incidence, indicating the positive impact of strict adherence to infection control measures in health care settings. #CDI#InfectionControl